Method and apparatus to conduct kinetic analysis of platelet function in whole blood samples

• US 20110086363A1
• Filed: 10/05/2010
• Published: 04/14/2011
• Est. Priority Date: 10/06/2009
• Status: Abandoned Application

• Current Assignee: University of Windsor
• Original Assignee: University of Windsor
• Inventors: Kaur, Harmanpreet, Carriveau, Edward C.J., Mutus, Bulent
• Application Number:
  US12/923,729
• Publication Number:
  US 20110086363A1
• Time in Patent Office: Days
• US Class Current: 435/7.1
• CPC Class Codes: B01L 3/502707 characterised by the manufacture of the container or its components by shaping or joining plastic parts B29C59/00, B29C65/00; by laminating B32B37/00; manufacture of microstructural devices in general B81C
• CPC Class Codes: G01N 33/86 involving blood coagulating time or factors, or their receptors

Abstract

Adhesion of platelets to blood vessel walls is the first step that promotes arrest of bleeding by interaction of the platelet receptors with various extracellular matrix proteins that become exposed on vascular injury. A flow chamber is provided for use in analyzing or studying platelet function, in whole blood, either as part of a batch process or in real time. In the flow chambers, an inert polydimethylsiloxane (PDMS) surface is plasma-activated and a homobifunctional cross-linker is used to immobilize platelet-binding proteins onto a chamber wall surface. Immobilized collagen and fibrinogen may thus be assayed by continuously monitoring the adhesion of ADP and Ca²⁺ activated platelets from a subject, such as a patient having normal or type 2 diabetes (T2D). The flow chamber provides a simplified and robust method for the construction flow chambers which enable the kinetic monitoring of platelet adhesion in whole blood.

Claims

1. An apparatus for the monitoring or assay of blood platelet adhesion or aggregation, the apparatus including a sample flow chamber, a blood flow inlet providing fluid communication into the flow chamber and a blood flow outlet providing fluid communication from said flow chamber,

said flow chamber being defined in part by a plurality of sidewalls, and at least one optically transparent wall portion,

the at least one said optically transparent wall portion having a chemically inert substrate having a polydimethylsiloxane PDMS compound coated thereon.

2. The apparatus of claim 1 wherein said monitoring or assaying of blood platelet adhesion comprises empirically measuring blood platelets adhered to the chemically inert substrate within the flow chamber as a measure of blood platelet immobilization.

3. The apparatus of claim 1 wherein said PDMS compound comprises a substantially inert plasma oxidized compound.

4. The apparatus of claim 3 wherein said transparent wall portion comprises a first chamber end wall, said flow chamber is defined in part by a second optically transparent end wall spaced from the first chamber end wall, at least one of the end walls being sized for optically coupling to an inverted optical microscope.

5. The apparatus as claimed in claim 4 wherein the chamber sidewalls comprise PTFE or a PTFE substrate.

6. The apparatus as claimed in claim 5 further including a fluid pump assembly operable to effect a blood sample fluid flow from the blood inlet across said flow chamber and outwardly from said flow chamber via said flow outlet at a rate of 0.5 to 10 ml/per minute and preferably about 2 ml/min.

7. The apparatus as claimed in claim 1 wherein said blood inlet is provided through a first one of said sidewalls, and said flow outlet is provided through a second other opposite sidewall, the blood inlet and outlet being offset with respect to each other to define a non-linear fluid flow path therebetween.

8. The apparatus as claimed in claim 6 wherein the flow inlet and the flow outlet have a spacing selected to provide a laminar, shearing flow therebetween.

9. The apparatus as claimed in claim 8 wherein said flow chamber has a volume selected at between about 0.025 cm³ and 4 cm³, and preferably about 1.0 cm³.

10. Use of the apparatus of claim 3 to optically monitor the therapeutic benefit of a selected hematological treatment agent on a blood platelet function in a blood sample extracted from a patient, said use comprising the steps of;

passing a volume of said blood sample through said flow chamber for a selected period of time; and

measuring the platelet adhesion adhered to the inert oxidized compound within the chamber.

11. Use as claimed in claim 9 wherein said hematological treatment agent comprises a medicament selected from the group consisting of Coumadin, Warfarin, Plavix and an other blood thinner.

12. Use as claimed in claim 11 wherein said step of measuring comprises optically measuring said adhered platelets using an optical microscope.

13. Use as claimed in claim 10 wherein said blood sample comprises a whole blood sample from a patient suffering from a malady selected from the group consisting of Type 2 diabetes, hemophilia, percutaneous coronary intervention, coronary artery disease and coronary stent implantation.

14. A method of making the apparatus of claim 1 comprising the steps of,

applying the PDMS compound coating to at least part of the optically transparent wall portion, and

oxidizing the PDMS compound using a plasma cleaner.

15. The method of claim 14 comprising the further step of applying a homobifunctional cross-linker to the PDMS compound to immobilize platelet binding proteins to less than about 10%, and preferably less that about 2% of a surface area of the transparent wall portion.

16. The method of claim 15 wherein said surface area is located generally at a central axial region of the flow chamber.

17. The method of claim 14 wherein said step of applying the cross-linker comprises adding 1 to 5% by weight, and preferably about 2% by weight aminopropyltrimethoxysilane to a 0.5 to 3 mm diameter section of said transparent wall portion,

applying 0.2 to 1 nM, and preferably 0.5 mM disuccinimidyl substrate solution to said section, and

applying to the section a solution selected from a collagen type 1 solution and a fibrinogen solution prior to buffering.